Terms: = Colorectal cancer AND SOCS1, O15524, 8651, ENSG00000185338, SOCS-1, SSI-1, SSI1, Cish1, JAB, CISH1, CIS1, TIP3 AND Treatment
16 results:
1. Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.
Ahluwalia P; Mondal AK; Ahluwalia M; Sahajpal NS; Jones K; Jilani Y; Gahlay GK; Barrett A; Kota V; Rojiani AM; Kolhe R
Cancer Med; 2022 Mar; 11(6):1573-1586. PubMed ID: 35137551
[TBL] [Abstract] [Full Text] [Related]
2. 5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.
Adamowicz M; Milkiewicz P; Kempinska-Podhorodecka A
J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 34987126
[TBL] [Abstract] [Full Text] [Related]
3. MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer.
Pourdavoud P; Pakzad B; Mosallaei M; Saadatian Z; Esmaeilzadeh E; Alimolaie A; Shaygannejad A
Mol Biol Rep; 2020 Dec; 47(12):9913-9920. PubMed ID: 33130965
[TBL] [Abstract] [Full Text] [Related]
4. socs1 Represses Fractionated Ionizing Radiation-Induced EMT Signaling Pathways through the Counter-Regulation of ROS-Scavenging and ROS-Generating Systems.
Kim S; Kim SH; Lee CE
Cell Physiol Biochem; 2020 Oct; 54(5):1026-1040. PubMed ID: 33048478
[TBL] [Abstract] [Full Text] [Related]
5. Comparative Oncologic Outcomes of Upper Third Rectal cancers: A Meta-analysis.
Clancy C; Flanagan M; Marinello F; O'Neill BD; McNamara D; Burke JP
Clin Colorectal Cancer; 2019 Dec; 18(4):e361-e367. PubMed ID: 31445919
[TBL] [Abstract] [Full Text] [Related]
6. Association of CHFR Promoter Methylation with treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic colorectal cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Value of Methylator Phenotype in Stage III Colon cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
8. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
[TBL] [Abstract] [Full Text] [Related]
9. Mechanism of suppressors of cytokine signaling 1 inhibition of epithelial-mesenchymal transition signaling through ROS regulation in colon cancer cells: suppression of Src leading to thioredoxin up-regulation.
Jung SH; Kim SM; Lee CE
Oncotarget; 2016 Sep; 7(38):62559-62571. PubMed ID: 27613835
[TBL] [Abstract] [Full Text] [Related]
10. Promoter methylation and expression of socs-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer.
Kang XC; Chen ML; Yang F; Gao BQ; Yang QH; Zheng WW; Hao S
Biomed Pharmacother; 2016 May; 80():23-29. PubMed ID: 27133036
[TBL] [Abstract] [Full Text] [Related]
11. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract] [Full Text] [Related]
12. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract] [Full Text] [Related]
13. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.
Jo P; Jung K; Grade M; Conradi LC; Wolff HA; Kitz J; Becker H; Rüschoff J; Hartmann A; Beissbarth T; Müller-Dornieden A; Ghadimi M; Schneider-Stock R; Gaedcke J
Surgery; 2012 Apr; 151(4):564-70. PubMed ID: 22001634
[TBL] [Abstract] [Full Text] [Related]
14. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
[TBL] [Abstract] [Full Text] [Related]
15. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Goel A; Xicola RM; Nguyen TP; Doyle BJ; Sohn VR; Bandipalliam P; Rozek LS; Reyes J; Cordero C; Balaguer F; Castells A; Jover R; Andreu M; Syngal S; Boland CR; Llor X
Gastroenterology; 2010 May; 138(5):1854-62. PubMed ID: 20102720
[TBL] [Abstract] [Full Text] [Related]
16. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS
Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756
[TBL] [Abstract] [Full Text] [Related]
